Back to DE D. E. Shaw & Co., Inc.

RARERARE
29 quarters

Position history for DED. E. Shaw & Co., Inc.'s holdings in ULTRAGENYX PHARMACEUTICAL IN

D. E. Shaw & Co., Inc. holds 1.3M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), worth $26.4M as of 2026-Q1. The position was increased (+265.8% shares). RARE represents 0.0% of D. E. Shaw & Co., Inc.'s portfolio.

Current Value

$26.4M

Current Shares

1.3M

Total Value Change

+$12.4M

Total Shares Change

+939,184

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
1.3M
+265.8%
$26.4M0.0%$22.07
46
2025-Q4
Increased
344,763
+45.1%
$7.9M0.0%$22.78
37
2025-Q3
Decreased
237,640
-56.1%
$7.1M0.0%$30.36
0
2025-Q2
Decreased
540,801
-2.8%
$19.7M0.0%$36.52
0
2025-Q1
Increased
556,417
+94.5%
$20.1M0.0%$37.82
45
2024-Q4
Increased
286,079
+9.4%
$12M0.0%$42.27
31
2024-Q3
Increased
261,594
+28.6%
$14.5M0.0%$54.43
35
2024-Q2
New
203,442
-
$8.4M0.0%$41.10
38
2023-Q4
Exited
0
-100.0%
$00.0%$47.82
0
2023-Q3
Decreased
6,152
-93.5%
$219,3190.0%$35.65
0
2023-Q2
Decreased
94,929
-21.5%
$4.4M0.0%$46.65
0
2023-Q1
Decreased
120,888
-58.3%
$4.8M0.0%$38.64
0
2022-Q4
Decreased
289,995
-38.6%
$13.4M0.0%$46.33
0
2022-Q3
Increased
472,354
+31.4%
$19.6M0.0%$40.55
36
2022-Q2
Decreased
359,517
-25.8%
$21.4M0.0%$60.24
0
2022-Q1
Decreased
484,338
-11.4%
$35.2M0.0%$71.36
0
2021-Q4
Increased
546,591
+14.9%
$46M0.0%$84.25
33
2021-Q3
Decreased
475,707
-37.9%
$42.9M0.0%$86.12
0
2021-Q2
Increased
766,097
+2.0%
$73M0.1%$96.29
30
2021-Q1
Increased
751,168
+5.0%
$85.5M0.1%$112.06
31
2020-Q4
Increased
715,287
+66.0%
$99M0.1%$144.37
44
2020-Q3
Increased
430,892
+27.8%
$35.4M0.0%$85.10
36
2020-Q2
Decreased
337,164
-15.4%
$26.4M0.0%$73.66
0
2020-Q1
Increased
398,474
+26.8%
$17.7M0.0%$44.32
35
2019-Q4
Increased
314,168
+66.8%
$13.4M0.0%$42.69
41
2019-Q3
Increased
188,383
+41.0%
$8.1M0.0%$42.50
37
2019-Q2
Decreased
133,606
-7.3%
$8.5M0.0%$63.50
0
2019-Q1
Decreased
144,177
-55.2%
$10M0.0%$69.36
0
2018-Q4
New
321,834
-
$14M0.0%$41.87
39

Other major holders of RARE: Capital Research Global Investors, Capital International Investors, FEDERATED HERMES, INC.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used